Eotaxin, an inducer of eosinophil migration and activation, exerts its activity by binding to CCR3, the C-C chemokine receptor 3. An inhibitor of the eotaxin-CCR3 binding interaction may have potential as an anti-inflammatory drug for treatment of asthma, parasitic infections, and allergic disorders. A radioligand binding assay was developed using HEK cells transfected with CCR3, with 125 I eotaxin as the ligand. Whole cells grown on polylysine-coated plates were used as the receptor source for the screen. Screening of more than 200,000 compounds with this assay yielded a number of screening hits, and of these, 2 active novel antagonists were identified. These compounds showed inhibitory effects on eosinophil chemotaxis in both in vitro and in vivo assays. (Journal of Biomolecular Screening 2003:324-331) 
INTRODUCTION

H UMAN EOSINOPHILS ARE PROINFLAMMATORY GRANULO-
CYTES that play an important role in several inflammatory diseases, including asthma, 1 atopic dermatitis, 2 and allergic rhinitis. 3 Among the cells that are recruited to the site of inflammation, the most important in causing damage in asthma appears to be the eosinophils. Eosinophils generate toxic proteins and free radicals that damage the bronchial and lung tissue, inducing airway hyperresponsiveness. Blocking the migration and activation of eosinophils to prevent lung tissue damage should thus provide a new treatment option for asthma. Eotaxin (CCL-11), a member of the C-C chemokine family of proteins, is the most potent and selective eosinophil chemoattractant and is believed to play an important role in the selective recruitment and activation of eosinophils into areas of inflammation.
4 CCR3 (C-C chemokine receptor 3), a 7-transmembrane domain G protein-coupled receptor, was identified as the eotaxin binding receptor on human eosinophils. These receptors can also bind RANTES (regulated on activation T cell expressed and secreted) and monocyte chemotactic protein (MCP). 5 CCR3 is expressed not only on eosinophils but also on basophils, mast cells, and T lymphocytes. [6] [7] [8] [9] [10] Several studies have shown that binding of eotaxin to CCR3 plays a significant role in the downstream signaling events, which results in the activation and accumulation of eosinophils in allergic asthma. With the steady rise in the incidence of asthma in developed countries, more effective ways of ameliorating this distressing and even lifethreatening disease are continually being investigated, and an inhibitor of eotaxin-CCR3 binding may have clinical potential in asthma treatment. 6, 11, 12 In recent years, several new classes of CCR3 antagonists that were active in eosinophil chemotaxis assays have been discovered by different research groups. [13] [14] [15] [16] [17] Information on the in vivo activity of these compounds has yet to be published.
Herein, we report the development of a simple, robust, and reproducible screening assay for discovering antagonists of CCR3-eotaxin-1 interactions. Using this high-throughput whole-cell receptor-binding assay, we have screened more than 200,000 compounds, which resulted in the identification of a novel class of CCR3 antagonists. The lead compounds were characterized in functional calcium assays, and their inhibitory effects on eosinophil chemotaxis were determined both in vitro and in vivo.
MATERIALS AND METHODS
Cloning and expression of CCR3 cell lines for radioligand binding assay and FLIPR-based Ca
2+ assay
The eotaxin receptor gene was cloned by PCR from cDNA isolated from eosinophils from an allergic individual. RNA was iso-lated from approximately 1 × 10 5 eosinophils using Trizol (Invitrogen, Carlsbad, CA) following the manufacturer's recommended protocol. Then, 1 µg of total RNA was reverse-transcribed into cDNA using SuperScript II (Invitrogen), and 5 µL of the resulting cDNA was used as a template for PCR using the enzyme Elongase (Invitrogen). PCR primers were designed to amplify the full-length gene with restriction enzyme sites on either end to facilitate cloning into a puromycin derivative of pCI (Promega, Madison, WI). This vector was constructed by cloning a puromycin resistance cassette (Clontech, Palo Alto, CA) into the BamH1 site of this vector. PCR with the following primers, 5′gctagaattcatgacaacctcactagatacagtt and 5′gcatgcggccgcctaaaacacaatagagagt, resulted in a product of approximately 1 KBp. Vector and PCR product were digested with EcoR1 and Not1 and ligated together at 4°C overnight with 1 U T4 ligase (Invitrogen) following the manufacturer's recommended protocol. The ligation mixture was transformed into maximumefficiency DH5 alpha cells to yield ampicillin-resistant colonies. Colonies were screened by PCR to identify recombinant clones. Recombinant clones were sequence confirmed to match the National Center for Biotechnology Information (NCBI) reference sequence for CCR3, NM_001837.
The CCR3-containing vector was transfected into HEK cells by calcium phosphate transfection (Profection kit, Promega), transfected clones were identified by selection in Puromycin (1.25 µg/mL), and CCR3 surface expression was assessed by 125 I eotaxin binding. A flag tag was added to the N-terminus of the CCR3 by PCR, and the resultant Flag-CCR3 gene was also ligated into pCIpuro. This vector was electroporated into the L1.2 cells, and they were selected by growth in 1.25 µg/mL puromycin followed by Dynabead sorting using an anti-flag antibody (Sigma Aldrich, St. Louis, MO) conjugated to antimouse antibody-coated Dynabeads (Dynal Biotech, Oslo, Norway). The resultant positive population was single cell cloned and assessed for CCR3 expression by calcium flux measured on the Fluorescence Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, CA).
Development of
125
I eotaxin binding assay using cell membrane HEK 293 cells transfected with CCR3 were maintained in Dulbecco's Modified Eagle Medium (Invitrogen) with 10% fetal bovine serum (Invitrogen) with 125 µg/mL puromycin. At 90% confluency of the cells, the media were removed, and the cells were harvested with homogenization buffer (RPMI 1640 without phenol red [pH 7.2] and 10 mM HEPES). The cells were homogenized with a polytron and centrifuged at 18,000 rpm for 10 min at 4°C. The supernatant was removed and the pellet was resuspended in homogenization buffer. The cells were homogenized again and centrifuged at 18,000 rpm for 10 min at 4°C. The supernatant was removed and the pellet was resuspended in homogenization buffer. The protein was quantified using the BCA kit (Pierce Chemical, Rockford, IL was added in place of the buffer. After incubating at room temperature for 180 min, the plate was harvested onto a Unifilter-C plate (Packard, Meriden, CT) soaked in 0.5% PEI. The plate was washed 5 times with wash buffer (eotaxin buffer with 0.5 M NaCl) and then dried in a vacuum oven. The bottom of the plate was sealed, and 30 µL of Microscint-O (Packard) was added to the wells. The top of the plate was sealed using TOPSEAL microplate sealing film (Packard), and the bound radioactivity was counted using a Topcount microplate scintillation counter (Packard).
Development of
125
I eotaxin binding assay using whole-cell suspension
A binding assay with whole cells was developed using cell suspensions prepared by dissociating the cell monolayer and resuspending to 5 × 10 6 cells/mL in eotaxin binding buffer. To a 96-well plate, 50 µL of binding buffer was added, followed by 100 µL of cell suspension. To the nonspecific control wells, a final concentration of 250 nM unlabeled eotaxin-1 was included in the buffer.
125
I eotaxin was added to the wells to a final concentration of 50 pM and incubated at room temperature with gentle shaking. After 3-h incubations, the reactions were harvested onto a glass fiber filter plate (GF-C, Packard), which was soaked in 0.5% PEI. The filter plates were washed 5 times with wash buffer and dried, and then Microscint-O was added, sealed, and counted on a Topcount.
Development of
125
I eotaxin binding assay using whole cells
The day before the assay, the cells were detached and resuspended in fresh medium to a cell density of 1 × 10 6 cells per mL. Then, 100 µL of cell suspension was added to the wells of a polylysine biocoat 96-well plate (Becton Dickinson Labware, Bedford, MA) and incubated overnight. The media were removed, and 75 µL of eotaxin binding buffer was added to the well.
125
I eotaxin (200 pM in 25 µL of eotaxin binding buffer) was added to the wells and incubated for 3 h with constant gentle rotation at room temperature. Nonspecific wells contained 250 nM cold eotaxin-1. The wells were washed 4 times with wash buffer and air-dried for 10 min. After adding 50 µL of Microscint-20 (Packard), plates were sealed and counted on a Topcount microplate scintillation counter.
Eotaxin binding assay for high-throughput screening
The test compounds were formatted using a 12 × 12 orthogonal mixing strategy as previously described. 18 The compounds were delivered to the bottom of the plate at a final concentration of approximately 10 µM of individual compound in DMSO. The DMSO was removed by drying in a Genevac Atlas HT12 (Genevac, Sproughton, England). The eotaxin binding buffer was added to solubilize the compounds, and the plates were placed on a shaker for 30 min. The solubilized compounds were transferred to the plates containing cells after removing the growth media and incubated for 30 min at room temperature with constant shaking. The binding assay was then performed as outlined before. A control plate containing 6 wells with no drugs for total counts and 6 wells containing unlabeled eotaxin-1 for the nonspecific background counts was used for calculating percent inhibition by the compounds.
Intracellular calcium assay
The calcium assay was performed using the murine L1.2 pre-B cell line transfected with CCR3. The cells were maintained in RPMI 1640 with 10% fetal bovine serum with puromycin. Prior to the experiment, cells were spun down and washed once with PBS (Invitrogen). The cell concentration was adjusted to 5 ×10 6 cells per mL. Cells were loaded with Fluo-3 AM (Molecular Probes, Eugene, OR) at a concentration of 5 µg/mL in loading buffer (20 mM HEPES [pH 7.4], 120 mM NaCl, 2 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 0.1% BSA, 5 mM glucose, and 0.08% pluronic acid) and incubated at room temperature in the dark for 45 min. The cells were washed 3 times and were resuspended at 1 × 10 7 cells/mL in FLIPR buffer (20 mM HEPES [pH 7.4], 120 mM NaCl, 2 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 0.1% BSA, and 5 mM glucose). Then, 100 µl of the cell suspension was added per well to the black clear-bottom plates (Corning Incorporated, Acton, MA). The calcium measurement was performed using FLIPR. The fluorescence excitation was set at 488 nm using an Argon ion laser as the excitation source, and emission was monitored at 540 nm using an appropriate filter. The FLIPR cooled charge-coupled device (CCD) camera was set to take pictures every 5 sec. Prior to loading the cell plate in the FLIPR chamber, cells were settled to the bottom of the plate by gentle centrifugation. The compounds to be tested were diluted to the appropriate concentration and placed in the FLIPR assay chamber, and 25 µL of each was added by the FLIPR pipettor. The increase in fluorescence was monitored if the test compound was an agonist. To demonstrate the antagonistic activity of a compound, 25 µL of 20 nM eotaxin-1 was added to the cell plate. The level of increase in fluorescence was measured for 360 sec, and the maximum fluorescence at the calcium peak was calculated using the FLIPR software.
Eosinophil assay
Whole human blood was obtained by venipuncture and layered on Polymorphprep to prepare granulocytes. Granulocytes were then incubated with anti-CD-16 antibody coupled with iron and then passed over a magnetic column to remove polymorphonuclear granulocyctes (PMNs).
Cells were suspended at 1.5 × 10 6 /mL, and chemotaxis was performed in a 48-well modified Boyden chamber (NeuroProbe Inc., Gaithersburg, MD) with a 5-mM pore polyvinylpyrrolidone (PVP)-free polycarbonate filter for 1 h at 37°C. The filters were removed from the Boyden chamber, dried, and stained with hematoxylin, and the cells were counted.
Mouse model of eotaxin-induced cellular influx
Balb/c mice obtained from Charles River (Portage, MI) were kept in an animal facility approved by the Association for Assessment of Laboratory Animal Care (AALAC), and the mice had access to water and food ad libitum. All animal work was done with an approved Institutional Animal Care and Use Committee (IACUC) protocol. Murine recombinant eotaxin was purchased from PreproTech (Rocky Hill, NJ). Interleukin-5 (IL-5) was purchased from R&D Systems (Minneapolis, MN) .
Eotaxin was dissolved in sterile saline (Abbott Laboratories, North Chicago, IL) for injection. The injection site was cleaned with saline, and then 0.1 mL of the solution was injected into the peritoneal cavity of mice. Mice were primed with IL-5 (100 ng), which was injected intravenously in the lateral tail vein 30 min prior to the injection of eotaxin. Experimental compounds were given orally 15 min prior to eotaxin. The animals were euthanatized with CO 2 and the peritoneal cavity lavaged with PBS containing 10 U/mL heparin (Sigma Chemical, St. Louis, MO). Total cell counts were determined by a Coulter Counter model Zb (Coulter, Hialeah, FL). Differential cell counts were done after cytocentrifugation (Cytospin Shandon/Lipshaw, Pittsburgh, PA) and staining with Wrights-Giemsa stain.
RESULTS AND DISCUSSION
Assay development and validation
Once the stably expressed HEK cells were available for assay development, a membrane preparation was made and an assay was set up to determine the binding parameters. As shown in Figure  1A , no specific binding was evident at any of the protein concentrations tested. This experiment was repeated several times with similar results.
The wells without any protein showed an average of 1000 counts (data not shown) due to the stickiness of the label contributing to the inherent nonspecific binding. Soaking the filter plates in PEI and washing the filters with high-salt wash buffer did not completely eliminate the nonspecific binding of the radioactive eotaxin to the filter.
A binding assay with the CCR3-transfected cell line was performed using cell suspensions as the receptor source and harvesting the cells onto a filter plate after the incubation. A similar experiment performed with untransfected wild-type HEK cells showed no difference in the total counts between transfected cell lines and the wild-type HEK cells (Fig. 1B) . Also, the cold eotaxin failed to compete the binding, which indicated that there was no specific binding of eotaxin to CCR3. As in the previous experiments, soaking the filter plates in 0.5% PEI and washing the filters with wash buffer containing 0.5 M NaCl did not eliminate the nonspecific binding. The experiment was repeated in several different formats, including a scintillation proximity assay (SPA) using wheat germ agglutinin beads (Amersham Biosciences, Piscataway, NJ) and flash plates (Perkin-Elmer Lifescience), with negative results.
The next assay format attempted was growing whole cells in polylysine-coated plates, as described in the Materials and Methods section. As shown in Figure 1C , there was a difference in binding observed between the transfected and untransfected cells. Also, there was 70% specific binding when 250 nM of cold eotaxin-1 was used to define the nonspecific binding. This experiment was repeated several times with reproducible results.
Once an assay format was established, optimization of the assay conditions for high-throughput screening (HTS) was initiated. Cell number was the first parameter examined to establish a robust total-to-nonspecific ratio. Various numbers of cells ranging from 50,000 to 500,000 cells/well were plated for overnight incubation. Figure 2A shows that the binding of 125 I eotaxin to CCR3 increased with the number of cells added to the wells, showing the receptor dependency of the binding. Because good signal to background was achieved by 1 × 10 6 cell per mL, it was decided to continue optimization using this cell concentration. An experiment was performed to determine the optimal concentration of the 125 I eotaxin to be used in the assay. As shown in the graph (Fig. 2B) , the total binding and the specific counts increased with increasing concentration of the 125 I eotaxin. It was decided to use 50 pM concentration of the radiolabel to reduce excessive usage of the radioactivity while maintaining a good total-to-nonspecific binding ratio. It was also noted that only less than 10% of the total 125 I eotaxin added in the wells bound to the receptors, eliminating the possibility of ligand depletion during the assay. A time dependency study was performed to determine the optimal time of incubation. It can be noted from the graph (Fig. 2C ) that the binding reached equilibrium within 3 h, and further assays were performed under equilibrium binding conditions. The displacement of 125 I eotaxin from the CCR3-transfected HEK cells by unlabeled eotaxin was determined in a displacement-type binding experiment. The unlabeled eotaxin-1 was added at concentrations ranging from .0038 to 250 nM. The IC 50 value from the graph (Fig. 3 ) was determined to be 3 nM.
Because the compounds to be screened were routinely dissolved in DMSO, the effect of DMSO on the binding was evaluated (Fig. 4A) . Varying percentages ranging from 1% to 5% (v/v) of DMSO were added to the reaction wells; 5% DMSO inhibited the specific counts at 64%, whereas 1% inhibited the counts by 31%. Because the sample preparation area did not have the capability to pipet less than 1 µL of the drug accurately, the effect of less than 1% of DMSO in the assay was not investigated. The assay was determined to be extremely sensitive even to very low concentrations of DMSO; it was decided to dry the compound plates, and the eotaxin binding buffer was added to solubilize the compounds on the day of the screening. The drug concentration to be used in the screening was determined by analysis of scatterplots produced with compound concentrations of 5, 10, and 25 µM. From the scatterplot (Fig. 4B) , it was determined that 10 µM was the highest concentration possible with acceptable scatter for screening compounds. The Z factor 19 calculations showed that at 10 µM, a Z factor of 0.45 provides an acceptable screening assay.
HTS and hit evaluation
Following the validation of the assay, an HTS assay was initiated with a throughput of approximately 23,040 compounds per day, in a 12-compound mixture format. Plate-to-plate variability was minimal, as shown in Figure 5 , and the overall hit rate was low (0.01%). The scatterplot of each assay was evaluated, and any hit above the noise was flagged for verification of activity. The deconvoluted picks from the primary screen were tested as single compounds in duplicate, and the IC 50 curves were generated for the actives. From the screening, 168 compounds that blocked binding of 125 I eotaxin to CCR3 were identified. Figure 6 shows structures of 2 lead compounds, A-122057 and A-122058, belonging to a single class identified from the screen. The inhibitory curves of these compounds are shown in Figure 7A . A-122057 and A-122058 inhibited eotaxin binding with IC 50 values of 600 and 975 nM, respectively. These compounds, when tested in the functional assay, inhibited the intracellular calcium mobilization in CCR3 expressing L1.2 cells in the presence of eotaxin-1 (Fig. 7B) , showing that CCR3 Antagonists FIG. 4 . Development of high-throughput screening assay. (A) Effect of DMSO concentration on the assay. DMSO was added to the wells of the microplates at concentrations of 1%, 2%, and 5% of the total volume into total and nonspecific wells. From 31% to 64% inhibition of specific counts was detected with increasing concentration of DMSO. (B) Determination of drug concentration for the CCR3 binding assay. A scatterplot of percent inhibitions generated from 96 wells from a mixed-compound plate (12 compounds per well) tested at different compound concentrations of 5 µM, 10 µM, and 25 µM. Z factor is calculated using the following equation: Z = 1 -(3σ S + 3σ C )/|µ S -µ C |. σ S = sample mean standard deviation, σ C = nonspecific mean standard deviation, µ S = mean of the samples, µ C = mean of the nonspecific binding wells. To determine if these compounds would inhibit a functional assay, chemotaxis of eosinophils induced by eotaxin was measured. Both compounds inhibited the chemotaxis of eosinophils in a concentration-dependent manner, as shown in Figure 8A ,B. These data suggest that the compound identified, bound and blocked the functional activity of CCR3. To further characterize the activity of these compounds, they were tested in a murine model of eotaxininduced peritoneal eosinophilia. 20 The compounds, when dosed orally at a dose of 10 mg/kg, caused a reduction in the numbers of eosinophils found in the lavage from the peritoneal cavities of the mice injected with eotaxin (Fig. 9 ). In this model, there are limited macrophage or PMN contributions to the total cells in the lavage fluid, and no changes in the numbers of these cells were observed (data not shown).
CONCLUSIONS
A simple and robust assay suitable for identifying inhibitors of binding of eotaxin to CCR3 was developed and validated. Using this assay, we screened more than 200,000 compounds from the Abbott Laboratories drug repository. The assay had good reproducibility and low scatter, and it ran at a daily throughput of > 
20,000 compounds in a semiautomated workstation mode. The screen resulted in the identification of novel compounds, which inhibited the binding of eotaxin to CCR3 with functional antagonist activity. Also, these potent inhibitors are effective in reducing the influx of eosinophils in vivo and suggest that compounds such as the one described here may provide a new treatment for eosinophil-dependent diseases. 
